Effect of calcium chloride on recovery from neuromuscular block

Efficacy of calcium chloride supplementary to neostigmine on recovery from neuromuscular blockade. A randomized controlled study.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

PACTR

Registry ID

PACTR201811703495809

Enrollment

Registered

2018-11-14

Start date

2018-11-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Surgery

Interventions

neostigmine group.

Calcium chloride group.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients of either sex. 18 to 65 years old. ASA physical status I–III. scheduled for elective surgery under general anesthesia with intubation of the trachea, of an expected duration of = 60 min

Exclusion criteria

Exclusion criteria: Patients with the suspected difficult airway. Chronic obstructive pulmonary disease or bronchial asthma. BMI = 40. Neuromuscular diseases. Suspected malignant hyperthermia. Glaucoma. renal or hepatic dysfunction. Taking medications that could affect NMB agents action. Pregnant or lactating women. Patients with hypo or hypercalcemia. Hypo-albuminemia.

Design outcomes

Primary

Measure	Time frame
The Extubation time	—

Secondary

Measure	Time frame
1. Recovery time (time from administration of neostigmine till reaching TOF ratio = 0.9). 2. Core body temperature, sevoflurane concentration, serum ionized calcium level, and arterial blood PH at the time of neostigmine administration. 3. Total atracurium dose used during the surgery. 4. TOFr at 5,10,20,30 min after neostigmine administration and at PACU arrival. 5. Time from neostigmine administration to PACU arrival. 6. The incidence of a residual neuromuscular block (TOFr less than 0.9 on quantitative monitoring) 13, measured at the same intervals as TOFr. 7. PACU discharge time (time from PACU admission till reaching modified Aldrete's score of = 9).	—

Measure

Time frame

1. Recovery time (time from administration of neostigmine till reaching TOF ratio = 0.9). 2. Core body temperature, sevoflurane concentration, serum ionized calcium level, and arterial blood PH at the time of neostigmine administration. 3. Total atracurium dose used during the surgery. 4. TOFr at 5,10,20,30 min after neostigmine administration and at PACU arrival. 5. Time from neostigmine administration to PACU arrival. 6. The incidence of a residual neuromuscular block (TOFr less than 0.9 on quantitative monitoring) 13, measured at the same intervals as TOFr. 7. PACU discharge time (time from PACU admission till reaching modified Aldrete's score of = 9).

—

Countries

Egypt

Contacts

Public ContactSamah El Kenany

MD Lecturer of anesthesia surgical intensive care and pain management

Sk_20022000@yahoo.com00201002262557

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Aug 9, 2026